Atagabalin (PD-0200,390) is a drug developed by
Pfizer and related to
gabapentin, which similarly binds to the α2δ
calcium channels (
1 and
2).[1] It was under development as a treatment for
insomnia,[2][3][4] but was discontinued following unsatisfactory trial results.
^Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters. 20 (2): 461–4.
doi:
10.1016/j.bmcl.2009.11.118.
PMID20005103.
^Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research. 28 (10): 2610–27.
doi:
10.1007/s11095-011-0490-x.
PMID21681607.
S2CID22241527.
Atagabalin (PD-0200,390) is a drug developed by
Pfizer and related to
gabapentin, which similarly binds to the α2δ
calcium channels (
1 and
2).[1] It was under development as a treatment for
insomnia,[2][3][4] but was discontinued following unsatisfactory trial results.
^Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters. 20 (2): 461–4.
doi:
10.1016/j.bmcl.2009.11.118.
PMID20005103.
^Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research. 28 (10): 2610–27.
doi:
10.1007/s11095-011-0490-x.
PMID21681607.
S2CID22241527.